Quotient Sciences and Intrepid Labs have announced a strategic partnership aimed at leveraging artificial intelligence (AI) to revolutionize early-stage drug development. This multi-year collaboration will enable Quotient Sciences to utilize Intrepid’s innovative machine learning model, ANDROMEDA, which is designed to optimize the clinical performance of drug products.
ANDROMEDA facilitates the rapid exploration of formulation options, significantly reducing the experimental burden and enhancing data-driven decision-making. Unlike traditional large language models, this proprietary algorithm offers the potential for tailored client-specific models, thereby improving predictivity. This partnership builds on an existing collaboration where Intrepid’s AI capabilities were integrated into Quotient’s Translational Pharmaceutics® platform, further accelerating the transition of new drug products into clinical development.
The collaboration promises to enhance the formulation development process by combining Quotient Sciences’ extensive experience in GMP manufacturing with Intrepid Labs’ expertise in AI-guided formulation science. This synergy is expected to shorten development cycles and increase the likelihood of successful clinical outcomes. Both companies aim to explore additional applications of their partnership as it progresses, responding to an industry demand for more efficient R&D processes.
Get started today with Solo access →
